rss
Br J Ophthalmol doi:10.1136/bjo.2008.155531

A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: The VIA study

  1. Michael J Potter (michael.potter88{at}gmail.com),
  2. Cheryl C Claudio (cheryl.research{at}gmail.com),
  3. Shelagh M Szabo (shelagh.szabo{at}oxfordoutcomes.com)
  1. University of British Columbia, Canada
  2. University of British Columbia, Canada
  3. University of British Columbia, Canada
    • Published Online First 10 June 2009

    Abstract

    Aim: To determine if reduced light dose photodynamic therapy (PDT) combined with bevacizumab will decrease the number of bevacizumab treatments required over six months compared to bevacizumab monotherapy in neovascular age-related macular degeneration (AMD).

    Methods: Thirty-six patients with neovascular AMD were recruited for this randomised, double-masked, controlled clinical trial. Patients received intravitreal bevacizumab plus PDT using a light dose of either 25 J/cm2 (group 1) or 12 J/cm2 (group 2), or intravitreal bevacizumab plus sham PDT (group 3). Patients returned monthly for possible retreatment with bevacizumab or combination therapy (with a three-month minimum interval between combination treatments); retreatment decisions were primarily based on optical coherence tomography. The main outcome measure was the mean number of bevacizumab treatments required over six months.

    Results: Patients required a mean of 2.8 bevacizumab treatments in group 1 and 2.5 in group 2, compared to 5.1 in group 3 (p=0.005 and p<0.001, respectively).

    Conclusions: Combination bevacizumab and 25-J/cm2 or 12-J/cm2 PDT significantly reduced the number of bevacizumab treatments required over six months. This study was powered to examine number of treatments, but not visual acuities. Nevertheless, visual acuities responded favourably in all three groups. Further studies will be helpful to explore visual outcomes.

    This clinical trial was registered on ClinicalTrials.gov, Identifier NCT00359164.

    Relevant Articles

    • Clinical science: Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration
      • Ciro Costagliola,
      • Mario R Romano,
      • Michele Rinaldi,
      • Roberto dell'Omo,
      • Flavia Chiosi,
      • Massimo Menzione,
      • Francesco Semeraro
      Br J Ophthalmol 2010;94:180-184 Published Online First: 3 December 2009 doi:10.1136/bjo.2009.159343
    • At a glance: At a glance
      • Harminder S Dua,
      • Arun D Singh
      Br J Ophthalmol 2010;94:i doi:10.1136/bjo.2009.178830

    This Article

    1. Abstract
    2. PDF
    3. All Versions of this Article:
      1. bjo.2008.155531v1
      2. 94/2/174 most recent

    Responses

    1. Submit a response
    2. No responses published

    Social bookmarking

    Register for free content


    Free sample
     This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
    View free sample issue >>

    Free archive
    The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
    Register to access the free archive >>

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.